GVSAP collaborates with Biocytogen
May 22, 2024
Source: drugdu
76
GV Safety Assessment Platform (GVSAP), an integrated R&D enabler offering comprehensive preclinical research solutions, recently announced a partnership with Biocytogen. This collaboration aims to boost the R&D endeavours of Indian researchers by democratising tools and technologies.
According to a press release, through this alliance, Indian biomedical researchers will gain access to Biocytogen’s expertise in providing humanised research models, other off-the-shelf models and products, and Gene Targeting Services offered under Biocytogen’s sub-brand BioMice.
https://www.expresspharma.in/gvsap-collaborates-with-biocytogen/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology December 24, 2024
- Beware of “two sets of prices” providing funding sources for pharmaceutical bribery December 24, 2024
- Is placebo effective? Vertex evaporates $13 billion overnight December 24, 2024
- Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs December 24, 2024
- Novo Nordisk’s talent war December 24, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
